Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessia Ciafarone has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oral Nitrate-Reducing Bacteria and Nitric Oxide Homeostasis: Functional Host–Microbe Interactions in Oral and Vascular Health

    by Serena Altamura, Francesca Lombardi, Alessia Ciafarone, Paola Palumbo, Benedetta Cinque, Maria Grazia Cifone, Davide Pietropaoli

    Nitric oxide (NO) is a key regulator of vascular homeostasis and host–microbe interactions. In addition to the endogenous nitric oxide synthase (NOS) pathway, the enterosalivary nitrate–nitrite–NO pathway provides an alternative source of NO and critically depends on oral nitrate-reducing bacteria (ONRB). This review examines the oral microbiome–NO axis and its role in nitrate metabolism, NO homeostasis, and oral–systemic interactions. A narrative review integrating microbiological, mechanistic, and clinical evidence on oral nitrate metabolism, ONRB activity, and their impact on oral and systemic outcomes, including dietary and antiseptic interventions. The functional activity and nitrate-reducing capacity of the oral microbiome are key determinants of nitrate reduction and systemic NO bioavailability. Oral dysbiosis, periodontal disease, and antiseptic mouthwash use impair ONRB activity and nitrite production, potentially affecting vascular function and blood pressure. Conversely, dietary nitrate enhances ONRB activity and nitrate-to-nitrite conversion, supporting oral and vascular health. Interindividual variability, partly influenced by sex-related factors, may contribute to heterogeneous responses. The oral microbiome–NO axis represents a functional interface between host physiology and microbial metabolism, linking oral ecology with vascular regulation. Through their activity, ONRB contribute to NO homeostasis, highlighting nitrate bioactivation as an important component of host–microbe interactions with implications for oral and systemic physiology. Recognition of this pathway expands current understanding of host–microbe cooperation in NO homeostasis and may inform future microbiome-based approaches to support oral and cardiovascular health.

  • Open Access

    Oral Barrier Immunometabolism in Chronic Low-Grade Inflammation: Molecular Mechanisms and Systemic Implications

    by Aferdita Ademi, Skender Topi, Mitilda Gugu, Alessia Ciafarone, Maria Grazia Cifone, Davide Pietropaoli, Serena Altamura

    Chronic low-grade inflammation is a hallmark of aging and a major driver of metabolic and degenerative diseases. While systemic immune dysfunction has been widely investigated, the contribution of barrier tissues to persistent inflammatory signaling remains incompletely defined. The oral mucosa represents a uniquely exposed barrier, continuously challenged by microbial, mechanical, and metabolic stressors and characterized by a specialized immune architecture. Here, we synthesize current evidence supporting the oral barrier as an active immunometabolic interface linking local immune activation to systemic inflammatory tone. Spatially organized epithelial, neutrophil, and antigen-presenting cell (APC) compartments coordinate immune responses tightly coupled to metabolic reprogramming, including hypoxia-inducible factor-1α (HIF-1α)-dependent glycolysis and mitochondrial reactive oxygen species (mtROS) production. In parallel, the oral microbiota provides ligands and metabolites such as lipopolysaccharide (LPS), short-chain fatty acids (SCFAs), and succinate, which activate pattern-recognition receptors (PRRs), including toll-like receptors (TLRs) and the NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome, thereby sustaining nuclear factor kappa-light-chain-enhancer of activated B cell (NF-κB)-mediated inflammatory signaling. Barrier disruption and dysbiosis promote microbial translocation and persistent innate immune activation, while saliva and gingival crevicular fluid facilitate systemic dissemination of inflammatory mediators. Overall, sustained immunometabolic engagement at the oral barrier emerges as a key driver of chronic low-grade systemic inflammation and a potential therapeutic target in inflammaging.


  • Open Access

    The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma

    by Alessia Ciafarone, Paola Palumbo

    Chemotherapy has profoundly shaped modern oncology, evolving from early cytotoxic approaches to biologically informed strategies. In glioblastoma (GBM), the highly aggressive primary brain tumor, precision medicine does not rely on the identification of a single crucial oncogenic driver but integrates biologically informed stratification strategies to predict treatment response, resistance, and therapy-induced adaptation. This review recapitulates the historical milestones of chemotherapeutic development in neuro-oncology, with particular emphasis on GBM. As the main chemotherapeutic agent currently used in GBM, temozolomide (TMZ) initially represented a major therapeutic breakthrough; however, its clinical use has progressively unveiled the biological and clinical limitations of conventional cytotoxic paradigms. While TMZ exerts antitumor activity through DNA damage–induced apoptosis, accumulating experimental evidence indicates that it may also elicit adaptive responses, ultimately supporting tumor progression and therapy resistance. By integrating historical milestones with recent molecular understanding, this review highlights how improved knowledge of therapy-induced adaptations may inform emerging precision medicine strategies in GBM, underscoring the need for tailored treatments to overcome tumor heterogeneity and adaptive responses.


  • Open Access

    Correction: Ciafarone et al. Multi-Strain Probiotic Lysate Attenuates TGF-β1-Induced Intestinal Fibrosis and EMT Modulating Smad, Akt, and WNT/β-Catenin Pathways. Cells 2025, 14, 1432

    by Alessia Ciafarone, Serena Artone, Valeria Ciummo, Francesca Rosaria Augello, Serena Altamura, Francesca Lombardi, Giovanni Latella, Paola Palumbo, Benedetta Cinque

  • Open Access

    Inhibitory Effect of Levilactobacillus brevis on Salivary α‐Amylase: Evidence From In Vivo and In Vitro Study

    by Serena Altamura, Alessia Ciafarone, Francesca Rosaria Augello, Benedetta Cinque, Davide Pietropaoli, Paola Palumbo, Francesca Lombardi

    Scope: Human salivary α‐amylase (sAA) is a therapeutic target for various pathological oral conditions. Several studies have reported that different probiotic strains can inhibit α‐amylase in vitro . However, the mechanisms behind remain largely unknown. To explore this topic, we focused on Levilactobacillus brevis (L. brevis) , a probiotic species known for its beneficial effects on oral health. Methods and Results: The effect of L. brevis on sAA activity was evaluated in vivo by analyzing saliva samples from healthy subjects involved in a randomized, double‐blind, placebo‐controlled study. Additionally, we assessed the effects of probiotic lysate in vitro using a commercial sAA. An amylase‐binding assay was conducted to investigate the interaction between probiotic soluble components and the enzyme. Our findings demonstrate that L. brevis effectively inhibits α‐amylase activity, supporting its positive role in promoting both oral and systemic health. We also observed a similar effect on pancreatic α‐amylase. Conclusion: Our data provide the first evidence of a direct interaction between α‐amylase and bioactive molecules from L. brevis , suggesting that the observed effects could be due to the ability of these probiotic‐derived molecules to bind and inhibit α‐amylase activity. This research expands our understanding of the anticariogenic and antihyperglycemic properties of specific probiotics. Trial Registration: ClinicalTrials.gov identifier: NCT06457724


  • Open Access

    Exploring the Anticancer Potential of the Multistrain Probiotic Formulation OxxySlab in Bladder Cancer Cell Lines

    by Valeria Ciummo, Alessia Ciafarone, Serena Altamura, Francesca Lombardi, Marcella Reale, Maria Grazia Cifone, Benedetta Cinque, Paola Palumbo

    Bladder cancer (BC), particularly its muscle-invasive subtype (MIBC), remains a clinical challenge due to high recurrence and limited therapeutic options. Emerging evidence suggests that probiotics may offer selective anticancer effects while preserving healthy tissue. In this study, we evaluated the antitumor potential of OxxySlab, a multistrain probiotic formulation, in two BC cell lines (T24 and 5637) and a non-tumorigenic urothelial cell line (SV-HUC1). OxxySlab lysate dose-dependently inhibited BC cell proliferation, clonogenicity, and migration, while sparing normal cells. Mechanistically, the treatment suppressed epithelial–mesenchymal transition (EMT), induced senescence, and disrupted redox homeostasis in malignant cells. These effects were associated with the induction of oxidative stress and impaired antioxidant defenses. Co-treatment with vitamin C attenuated ROS accumulation and senescence, implicating oxidative stress as a key mediator. Notably, SV-HUC1 cells retained viability and phenotype, confirming the formulation’s selectivity. Overall, these findings support OxxySlab as a promising adjunctive strategy in BC therapy, capable of reducing tumor aggressiveness through redox-mediated senescence and EMT inhibition without harming normal urothelial cells.


  • Open Access

    Multi-Strain Probiotic Lysate Attenuates TGF-β1-Induced Intestinal Fibrosis and EMT Modulating Smad, Akt, and WNT/β-Catenin Pathways

    by Alessia Ciafarone, Serena Artone, Valeria Ciummo, Francesca Rosaria Augello, Serena Altamura, Francesca Lombardi, Giovanni Latella, Paola Palumbo, Benedetta Cinque

    Intestinal fibrosis is a common complication of inflammatory bowel diseases (IBD), and, to date, effective and safe antifibrotic drugs are still lacking. Emerging evidence suggests that probiotics may provide novel strategies to counteract fibrotic processes. In this study, we evaluated the anti-fibrotic potential of a multi-strain probiotic formulation, OxxySlabTM, using in vitro models of intestinal fibrosis and epithelial-to-mesenchymal transition (EMT). Human intestinal fibroblasts (CCD-18Co cell line) and epithelial cells (Caco-2 cell line, IECs) were stimulated with transforming growth factor-β1 (TGF-β1) to induce fibrotic and EMT phenotypes, respectively. Treatment with OxxySlab modulated cell proliferation and fibrosis-related markers, which we assessed through CCK-8 assay, Western blotting, and immunofluorescence. The probiotic lysate inhibited both canonical and non-canonical TGF-β1 signaling pathways, and it also reduced TGF-β1 gene expression in activated myofibroblasts, as shown by RT-qPCR. Furthermore, probiotic treatment reversed EMT features by restoring epithelial markers and downregulating mesenchymal markers. These findings highlight the beneficial effects of the multi-strain probiotic formulation as an adjunctive therapeutic agent targeting key pathways involved in intestinal fibrosis.


  • Open Access

    COX-2 Inhibition in Glioblastoma Cells Counteracts Resistance to Temozolomide by Inducing Oxidative Stress

    by Francesca Rosaria Augello, Francesca Lombardi, Valeria Ciummo, Alessia Ciafarone, Maria Grazia Cifone, Benedetta Cinque, Paola Palumbo

    Oxidative stress critically influences the pathophysiology of glioblastoma (GBM), a deadly and aggressive brain tumor. Reactive oxygen species (ROS) regulate cancer cell homeostasis, influencing the treatment response. The transcription factor Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) activates antioxidant defenses, protecting GBM cells from therapy-induced oxidative stress and contributing to Temozolomide (TMZ) resistance. Cyclooxygenase-2 (COX-2) plays a key role in GBM chemoresistance by modulating the tumor microenvironment and supporting a pro-survival phenotype. The impact of COX-2 inhibition by celecoxib (CXB), a selective COX-2 inhibitor, combined with TMZ on oxidative stress modulation linked to resistance was investigated in GBM primary cultures and cell lines. The drug combination CXB+TMZ was tested on TMZ-sensitive and -resistant cells, and ROS levels and Nrf2 activation were evaluated via a DCFH-DA probe and Western blotting, respectively. The oxidative stress marker malondialdehyde and antioxidant enzymes were assayed using standard methods. COX-2 inhibition combined with TMZ significantly increased ROS, while TMZ alone induced a compensatory antioxidant response, sustaining resistance. Drug combination reduced this response, restoring oxidative stress even in TMZ-resistant cells. Prostaglandin E2 reversed these effects, confirming the role of the COX-2/PGE2 axis in redox balance. Drug combination increased ROS, disrupted redox homeostasis and overcame TMZ resistance, supporting COX-2 inhibition as a promising GBM therapy strategy.


  • Open Access

    Efficacy of an Innovative Poly-Component Formulation in Counteracting Human Dermal Fibroblast Aging by Influencing Oxidative and Inflammatory Pathways

    by Francesca Rosaria Augello, Francesca Lombardi, Alessia Ciafarone, Valeria Ciummo, Serena Altamura, Maurizio Giuliani, Benedetta Cinque, Paola Palumbo

    Skin aging is characterized by reactive oxygen species (ROS) accumulation, principal players in triggering events associated with aging. Our recent data on the ability of an innovative poly-component formulation (KARISMA Rh Collagen® FACE: K formulation) to suppress the biomolecular events associated with oxidative stress-induced aging prompted us to deepen the mechanisms underlying the observed effects on aged human dermal fibroblasts (HDFs). Here, we evaluated K’s ability to perform a direct free radical-scavenging action and modulate anti-oxidant systems by counteracting the inflammatory process in an H2O2-induced cellular senescence model. Standard methods were used to measure scavenging capacity and enzymatic anti-oxidant system activities. Nuclear factor E2-related factor 2 (Nrf2) and nuclear factor kappa-B (NF-κB) levels were analyzed by Western blot. We assessed pro-inflammatory cytokines, matrix metalloproteinases (MMPs), and advanced glycation end-products (AGEs). Our results show that K counteracted stress-induced aging in a dose-dependent manner by exerting a direct scavenging action and increasing anti-oxidant systems, such as superoxide dismutase (SOD) and catalase (CAT) up to control values. These findings could be associated with increased phospho-Nrf2 (p-Nrf2) expression, generally reduced in aged HDFs following exposure to different concentrations of K formulation. Moreover, K formulation caused a reduction of pro-inflammatory cytokines, interleukin-1β and -6, MMP-1 and -9, and AGE levels, events related to a downregulation of p-NF-κB level. The results indicate that K formulation re-established the normal physiology of HDFs by reducing p-NF-κB expression and restoring Nrf2 activation, thus supporting its efficacious reparative and regenerative action in treating skin aging.